Regentatlantic Capital LLC Gilead Sciences, Inc. Transaction History

Regentatlantic Capital LLC

$3.34 Billion
Q3 2022

A detailed history of Regentatlantic Capital LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Regentatlantic Capital LLC holds 35,350 shares of GILD stock, worth $3.27 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

35,350

Previous 33,921 4.21%

Holding current value

$3.27 Million

Previous $2.1 Million 4.01%

% of portfolio

0.07%

Previous 0.07%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $85,082 - $97,186	1,429 Added 4.21%	35,350 $2.18 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $31,053 - $34,975	538 Added 1.61%	33,921 $2.1 Million
Q1 2022 May 02, 2022	SELL	$57.92 - $72.58 $93,772 - $117,507	-1,619 Reduced 4.63%	33,383 $1.99 Million
Q4 2021 Jan 27, 2022	BUY	$64.88 - $73.64 $56,834 - $64,508	876 Added 2.57%	35,002 $2.54 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $81,972 - $88,439	1,211 Added 3.68%	34,126 $2.38 Million
Q2 2021 Aug 12, 2021	BUY	$63.47 - $69.35 $59,027 - $64,495	930 Added 2.91%	32,915 $2.27 Million
Q1 2021 Apr 29, 2021	BUY	$60.0 - $68.46 $124,740 - $142,328	2,079 Added 6.95%	31,985 $2.07 Million
Q4 2020 Feb 04, 2021	SELL	$56.65 - $64.55 $1.22 Million - $1.39 Million	-21,479 Reduced 41.8%	29,906 $1.74 Million
Q3 2020 Oct 13, 2020	SELL	$62.1 - $78.08 $2.23 Million - $2.81 Million	-35,939 Reduced 41.16%	51,385 $3.25 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $3.28 Million - $3.81 Million	45,410 Added 108.34%	87,324 $6.72 Million
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $161,585 - $206,967	2,580 Added 6.56%	41,914 $3.13 Million
Q4 2019 Feb 04, 2020	SELL	$61.62 - $67.78 $564,932 - $621,407	-9,168 Reduced 18.9%	39,334 $2.56 Million
Q3 2019 Oct 22, 2019	BUY	$62.51 - $69.0 $118,331 - $130,617	1,893 Added 4.06%	48,502 $3.07 Million
Q2 2019 Jul 23, 2019	BUY	$61.87 - $69.38 $248,284 - $278,421	4,013 Added 9.42%	46,609 $3.15 Million
Q1 2019 May 03, 2019	BUY	$62.53 - $70.05 $555,641 - $622,464	8,886 Added 26.36%	42,596 $2.77 Million
Q4 2018 Jan 30, 2019	SELL	$60.54 - $79.0 $617,810 - $806,195	-10,205 Reduced 23.24%	33,710 $2.11 Million
Q3 2018 Oct 30, 2018	SELL	$71.28 - $78.92 $685,784 - $759,289	-9,621 Reduced 17.97%	43,915 $3.39 Million
Q2 2018 Jul 31, 2018	SELL	$64.88 - $75.68 $407,576 - $475,421	-6,282 Reduced 10.5%	53,536 $3.79 Million
Q1 2018 Apr 23, 2018	BUY	$72.84 - $88.8 $127,178 - $155,044	1,746 Added 3.01%	59,818 $4.51 Million
Q4 2017 Jan 23, 2018	BUY	$71.15 - $83.52 $223,909 - $262,837	3,147 Added 5.73%	58,072 $4.16 Million
Q3 2017 Oct 25, 2017	BUY	$72.11 - $85.47 $3.96 Million - $4.69 Million	54,925	54,925 $4.45 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regentatlantic Capital LLC with notifications on news.

Account

Regentatlantic Capital LLC Gilead Sciences, Inc. Transaction History